Background and aim: Colonoscopic perforation is a rare complication. We sought to determine its risk factors in patients with inflammatory bowel disease (IBD).
Introduction
Inflammatory bowel diseases (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), are chronic, progressive inflammatory conditions. Colonoscopy plays a critical role for diagnosis, differential diagnosis, treatment, and disease monitoring. 1, 2 In addition to diagnosis and surveillance for colorectal neoplasia, colonoscopy has been widely used a therapeutic modality such as stricture dilation. 3 However, complications, particularly colonoscopic perforation can occur in both diagnostic and therapeutic colonoscopy.
The reported frequencies of colonoscopy-associated perforation varied, ranging from 0.03% to 0.3% in the general population during screening and/or diagnostic colonoscopy. [4] [5] [6] [7] [8] [9] [10] [11] The risk of perforation is 1.9 times higher in colonoscopy with biopsy than that without. 12 Small studies attempting to examine the safety of screening and/or diagnostic colonoscopy in general population have also mentioned procedurerelated complications in patients with IBD. 13, 14 The safety of therapeutic endoscopy in IBD patients has also been evaluated in a meta-analysis in which major complications, such as bleeding and perforation were reported in 14 (2%) patients. Neither active disease at the time of dilatation nor medical therapy following stricture dilation affected long-term outcomes of endoscopic dilation in CD. 15 We had reported a large study using the National Inpatient Sample (NIS) in which IBD patients had a higher risk of colonoscopy-associated perforations than non-IBD controls. 16 In addition, older age, female patients and endoscopic dilations appeared to be associated with an increased risk for perforation in combined IBD and non-IBD patient populations. 16 However given the limitations of the database including inability to get information on the medications and disease activity and outcome and influence of endoscopist's factors, we wanted to study comprehensively the risk factors for perforation for IBD patients incorporating all these into account when studying the risk factors for perforation in this single-center study.
The aim of our study was to determine the risk factors for colonoscopic perforation in IBD patients undergoing colonoscopy in a tertiary care referral center. Also we wanted to study the morbidity and the outcome associated with the perforation in IBD patients.
Materials and methods

Patients
This single center case-control study was approved by the Cleveland Clinic Institutional Review Board. Consecutive IBD patients (both UC and CD) who underwent colonoscopy were identified from our electronic medical records with International Classification of Diseases, 9th revision codes (556.x and 555.x). The ICD codes were linked to Current Procedure Terminology (CPT) codes 45378 through 45385 for identifying these patients. There were a total of 5295 colonoscopies performed in IBD patients from January 2002 to October 2010. Perforations were identified using the ICD-9 codes for perforation of intestine and accidental puncture or laceration during a procedure (ICD-9 codes 569.83 and 998.2). A total of 19 patients were finally included in the study group. 76 patients with underlying IBD who underwent colonoscopy during the same study period and had no perforation were identified from the 5276 colonoscopies, who were matched based on the indication for colonoscopy, diagnostic and therapeutic (control group) in a 1:4 ratio.
Inclusion and exclusion criteria
The inclusion criteria were all patients (both inpatients and outpatients) with IBD who had colonoscopy. For the purpose of our primary analysis, we excluded discharges with a secondary diagnosis of colorectal cancer (ICD-9 CM code 1530-1543, 1548). Patients who got sigmoidoscopy or incomplete procedures were also excluded from the study.
We also calculated the number of patients getting colonoscopic interventions including stricture dilations (ICD-9 CM code 46.85) and colonoscopic biopsy.
Patients who had perforation complicating their colonoscopy performed at outside institutions or who came as transfers from outside institutions with complications were excluded.
Demographic and clinical variables
Demographic and clinical variables were studied including age, sex, ethnicity, body mass index (BMI), smoking and alcohol use, and family history of IBD, presence of PSC, concurrent autoimmune disorders, and significant comorbidities (liver, heart and renal diseases). In addition, IBD history including age of UC/CD diagnosis, extent and severity of colitis was obtained. Information was also obtained about the activity of IBD by symptoms and signs, imaging and/or endoscopy. The use of long-term medical therapy including corticosteroids (both oral and intravenous), immunomodulators including azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, and antibiotics (ciprofloxacin or metronidazole) was documented.
Bowel preparation was done using the standard 2-4 L of hypertonic polyethylene glycol solution or magnesium citrate starting 24 h before commencement of the procedure. Sedation was not given routinely or in a standardized fashion, but patient and endoscopist decided individually whether to use conscious sedation with benzodiazepines (diazepam or midazolam) and meperidine or to use deep sedation. All procedures were performed by 40 gastroenterologists, hepatologists and surgeons with varying levels of experience assisted by nurses trained to assist in endoscopic procedures. Standard video colonoscopes from Olympus (Olympus Optical Co. Ltd., Tokyo, Japan) were used for exams, both adult long and pediatric long.
Assessment of images
One expert endoscopist was invited to assess these images for disease activity. (B.S.) The expert endoscopist had performed more than 3000 colonoscopy procedures on IBD patients and was familiar with the disease activity of UC and CD as identified through endoscopy. The images were displayed to expert endoscopist independently. Each image was assessed and graded for inflammatory change in UC patients using the Schroeder (Mayo Score). 17 Disease activity was scored on a scale of 0-3 (Schroeder activity index). All images were displayed anonymously to the observer and revealed neither clinical data nor the date on which the images were taken. Assessment of disease activity by the endoscopist was correlated to the assessment by the original endoscopist doing the procedure. For patients with CD, we used the Simple Endoscopic Score for Crohn's disease. We classified severe disease if the score was greater than 16 based on previously used validation. 18 The endoscopic data recorded included the region involved (terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum); the nature of the involvement, was obtained from the database.
Endoscopist's information was obtained including whether they were IBD specialists or not. They were classified as IBD specialist if they spent more than 50% of their clinical care taking care of IBD patients.
Post perforation courses were reviewed to determine outcomes. Nonoperative management consisted of no surgical intervention and broad-spectrum intravenous antibiotics along with endoscopic clipping. Overall survival was calculated from the date of diagnosis of perforation to the date of death from all causes, including postoperative deaths.
Outcomes
Our primary outcome of interest was the assessment of risk factors of colonoscopic perforation. Our secondary outcome of interest was the evaluation of the length of stay and the outcome determined by mortality and morbidity in these patients.
Statistical analysis
Comparative analyses of patients who had perforation with IBD and IBD patients who were at a similar risk of perforation were performed, as well as assessments of associations with the likelihood of perforation. Comparisons of the study and control groups were performed using Fisher's exact, chisquare, or Wilcoxon rank sum tests. Univariable associations between the presence of perforation and categorical study variables were assessed using Fisher's exact test or a chisquare test. Associations between the presence of perforation and quantitative variables were assessed using Wald P-values from logistic regression models. Conditional logistic regression analyses were also used to estimate covariate-adjusted odds ratios (aOR) for the presence of perforation. The selected covariates were corticosteroid use, activity of the disease, extent of underlying disease, biopsies or no biopsies and the risks were, estimated for each variable in the multivariable models. R version 2.8.1 was used to carry out all analyses.
Results
Incidence of perforation
Among the 5295 colonoscopies performed in IBD patients, there were a total of 4815 done for diagnostic purposes Table 1 presents the demographic and clinical characteristics between the two groups with and without perforation matched based on indication for colonoscopy. Patients in the study group tended to be younger than those in the IBD group without perforation. There was no difference in the presence of comorbidities between the two groups. These patients were matched for the indication of colonoscopy (diagnostic and therapeutic). More patients with perforation in the IBD group than without perforation had undergone colonoscopic biopsy done during the procedure (98.7% vs. 73.7%, p = 0.001).
Comparison of demographic and clinical data
On univariate analysis, IBD disease activity on endoscopy and steroid use were associated with an increased risk for perforation (Table 2) . Comorbidity, age, sex, and race did not influence perforation risk.
Multivariate analysis to identify risk for perforation
On multi-variate analysis, severe disease [adjusted odds ratio (aOR) of 3.92, 95% confidence interval [CI]: (1.17-13.20)] and steroid treatment (aOR = 7.68; 95% CI: 1.48, 39.81) independently predicted the risk of perforation. Age, gender, comorbidities, disease extent, setting of colonoscopy (inpatient vs. outpatient), type of colonoscope used, dose of sedation and endoscopic interventions did not increase the risk for perforation (Table 3) .
Distribution of perforation
The distribution of perforations spanned the entire colon and the small bowel: rectum (n= 1; 5.3%), descending colon (n= 4; 21.1%), sigmoid colon (n = 4; 21.1%), transverse colon (n= 3; 15.8%), and small bowel (ileum) in 7 (36.8%).
Diagnosis and outcome of perforation
Perforation was diagnosed by plain radiography in 10/19 patients (52.2%), computed tomography in 4/19 (26.3%) and by direct visualization at the time of colonoscopy in 4/19 (21.1%) All the patients with perforation were hospitalized with a median length of stay of 10 days (range 2-23 days). All but one patient underwent surgery. One of the perforations was managed endoscopically by endoscopic clipping. There was no mortality and no re-admissions within the first month to the hospital. However these patients had morbidity with the most common complication being pulmonary (pneumonia and atelectasis) in 4/19 (21.1%) and wound infection in 3/19 (15.8%).
Discussion
To our knowledge, there has been one population based study from our group on the prevalence and risk factors for colonoscopic perforation in IBD patients. 16 However there were limitations of the study including lack of information on extent and activity of disease and associated medications and its impact on the outcome. We incorporated all these information in this single-center study and identified that severe disease on endoscopy and steroid treatment independently predicted the risk of perforation. Reported risk of perforation in outpatients getting screening/diagnostic colonoscopy varies from 0.09 to 0.2%. [4] [5] [6] [7] [8] [9] [10] [11] However, the general population could have included a small number of patients with underlying IBD. A few studies on the overall safety of colonoscopy in the general population have specifically mentioned colonoscopy related complications in IBD patients. 13, 14 Multiple studies have reported the safety of ileocolonoscopy in IBD patients. In a study of 34 patients with severe UC, no procedure-related complications were reported. 19 Subsequently, in a study of 85 consecutive patients with acute UC, the only complication in one patient was perforation related to colonic dilatation. 20 In a retrospective study of 384 UC patients undergoing surveillance colonoscopies, there was one patient with silent perforation with an underlying stricture. 21 Similarly, a separate study of IBD patients with 151 colonoscopies and 70 polypectomies reported no bleeding or perforation. 22 In a large series of IBD patients of 558 colonoscopies, three perforations were reported, two perforations occurred in patients with CD with strictures and one in a patient with UC. 2 This particular study included 251 inpatients (44.9%) and 307 outpatients (55.1%) and the reported complication rate was 0.7%. Among all these studies, IBD disease activity did not increase the risk of perforation.
In one of the largest single-center studies to date of colonoscopy related perforation in which we studied over 5000 colonoscopies over a 9 year period, we found that the rate of perforation is 0.3% which is much similar to the general population. Although the overall risk of perforation was not compared to general population in this study, the complication rates appear similar with the risk being 0.2% with diagnostic colonoscopy and 1.2% with therapeutic colonoscopy. Our results are different from previously published results in that severe disease on endoscopy and use of steroids increased the risk of perforation. This difference could be attributed to larger sample size in our study of perforation with a large number of patients studied. This is one of the largest single-center studies on the risk of perforation in IBD patients. Also patients seen in our center were much sicker which could have contributed to increased perforation rate. Also the use of steroids associated with increased perforation rate is a surrogate indicator of severe disease activity and the presence of severe disease along with steroid use indicates that a full colonoscopy may not be indicated in patients presenting with severe disease and is more likely to be associated with complications.
We did not identify increased age or female sex as a risk factor for perforation as identified in previous studies. 9, 12, 16 Previous studies have shown better care of IBD patients with IBD specialist than non-IBD specialists including frequency of surveillance colonoscopies, appropriate biochemical testing in patients on IBD-related medications. 23 However no previous studies have addressed the issue of safety of colonoscopy in these patients with an IBD specialist. This may be explained based on the fact that IBD specialists have experience with these patients over a prolonged period of time and may be better equipped to manage these patients and do procedures in them. However we did not identify that colonoscopy by an IBD specialist decreases the risk of perforation.
Also, the frequency of perforation correlates with the endoscopists' experience. 24 However we did not observe any relationship between the endoscopists experience and the risk of perforation in our study. We also did not observe any difference in the sedation and the type of colonoscope used with its relationship to the risk of perforation. The findings of our study have several clinical implications. With IBD patients being treated with biologics as well as immunomodulators and corticosteroids, the consequence of perforation may be more detrimental. In addition, the risk of postoperative complications for salvaging surgery may also be increased in patients with infliximab and corticosteroids. 25, 26 Infliximab use was associated with infectious complications, with an odds ratio of 2.7 in a multivariable analysis. 25 In study from our institution, preoperative infliximab use for UC was found to be associated with an increased risk of post-operative infectious complications. 26 Thus, patients with colonoscopy related perforation may land up in ileostomy and may not be able to undergo reconstruction in the immediate post-operative period.
In our study, we did not observe increased mortality in patients with perforation. Also the use of biologics did not appear to alter the outcome of patients who had iatrogenic perforation secondary to colonoscopy. However we did observe increased post-operative complications in the form of pneumonia and wound infections in 7/19 (36.9%). All but one patient required surgical intervention for perforation. Only one of the perforations was managed by endoscopic clipping which was visualized during colonoscopy. The remaining 18 patients underwent surgery. Of these 11 patients required ileostomy for a short period.
There are several limitations to our study. This is a retrospective case-control study which poses its inherent limitations. Also this study has selection bias with the study being from a single tertiary care referral center. Also the number of patients with perforation was low in this study limiting the ability to analyze all the variables of interest. The other limitation is that the assessment of UC activities were performed using endoscopic still images in our study, it would have been difficult for the investigator reviewing the images to distinguish spontaneous bleeding from traumatic bleeding which could have altered the assessment of the disease severity based on endoscopy. The risk of perforation is higher in therapeutic colonoscopy. In our case-control study, we matched the cases and controls for the indication of colonoscopy (diagnostic and therapeutic) and so we could not see the effect of endoscopic therapy as a variable in the multivariate analysis.
To conclude, there appears to be a higher risk of colonoscopy-associated perforation in IBD patients with active disease and on steroids. Future prospective studies on safety of colonoscopy in IBD patients are required, particularly in those undergoing therapeutic procedures.
